-
公开(公告)号:US09919041B2
公开(公告)日:2018-03-20
申请号:US14661689
申请日:2015-03-18
IPC分类号: A61K39/12 , G01N33/569 , C07K14/005 , C12N7/00 , A61K39/00
CPC分类号: A61K39/12 , A61K2039/545 , A61K2039/55 , A61K2039/552 , A61K2039/55511 , A61K2039/55566 , C07K14/005 , C12N7/00 , C12N2710/14143 , C12N2710/14163 , C12N2750/10022 , C12N2750/10034 , C12N2750/10051 , C12N2770/10034 , G01N33/56983
摘要: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
-
公开(公告)号:US09610345B2
公开(公告)日:2017-04-04
申请号:US15249158
申请日:2016-08-26
发明人: Michael B Roof , Phillip Wayne Hayes , Marc Allan Eichmeyer , Gregory Paul Nitzel , Merrill Lynn Schaeffer
CPC分类号: A61K39/12 , A61K2039/5252 , A61K2039/5256 , A61K2039/5258 , A61K2039/545 , A61K2039/552 , A61K2039/55516 , A61K2039/55555 , A61K2039/55566 , C12N7/00 , C12N2750/10022 , C12N2750/10023 , C12N2750/10034 , C12N2750/10051 , C12N2750/10071 , C12N2750/14143
摘要: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
-
公开(公告)号:US20190154688A1
公开(公告)日:2019-05-23
申请号:US16184018
申请日:2018-11-08
发明人: Arun V. Iyer , Joseph Ralph Hermann , Michael B. Roof , Eric Martin Vaughn , Merrill Lynn Schaeffer
IPC分类号: G01N33/569 , G01N33/68 , G01N33/50 , A61K39/12 , C12Q1/70 , C12P21/00 , A61K39/145 , C12N7/00 , C07K14/005
CPC分类号: G01N33/56983 , A61K39/12 , A61K39/145 , A61K2039/5252 , C07K14/005 , C07K2319/21 , C07K2319/50 , C12N7/00 , C12N2710/14021 , C12N2710/14022 , C12N2710/14043 , C12N2710/14051 , C12N2710/14143 , C12N2750/10034 , C12N2750/10051 , C12N2760/16134 , C12N2760/16151 , C12N2760/20022 , C12N2760/20034 , C12N2760/20051 , C12P21/00 , C12Q1/701 , G01N33/5091 , G01N33/6854 , G01N2333/01
摘要: The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.
-
公开(公告)号:US10168330B2
公开(公告)日:2019-01-01
申请号:US15061690
申请日:2016-03-04
发明人: Arun V. Iyer , Joseph Ralph Hermann , Michael B. Roof , Eric Martin Vaughn , Merrill Lynn Schaeffer
IPC分类号: G01N33/569 , C12N7/00 , C12P21/00 , A61K39/145 , C12Q1/70 , G01N33/68 , C07K14/005 , A61K39/12 , G01N33/50 , A61K39/00
摘要: The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.
-
公开(公告)号:US09669087B2
公开(公告)日:2017-06-06
申请号:US14661969
申请日:2015-03-18
发明人: Michael B Roof , Phillip Wayne Hayes , Marc Allan Eichmeyer , Gregory Paul Nitzel , Merrill Lynn Schaeffer
CPC分类号: A61K39/12 , A61K2039/5252 , A61K2039/5256 , A61K2039/5258 , A61K2039/545 , A61K2039/552 , A61K2039/55516 , A61K2039/55555 , A61K2039/55566 , C12N7/00 , C12N2750/10022 , C12N2750/10023 , C12N2750/10034 , C12N2750/10051 , C12N2750/10071 , C12N2750/14143
摘要: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
-
公开(公告)号:US10576142B2
公开(公告)日:2020-03-03
申请号:US15886531
申请日:2018-02-01
IPC分类号: A61K39/12 , G01N33/569 , C07K14/005 , C12N7/00 , A61K39/00
摘要: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
-
公开(公告)号:US20180236057A1
公开(公告)日:2018-08-23
申请号:US15957663
申请日:2018-04-19
发明人: Michael B. Roof , Phillip Wayne Hayes , Marc Allan Eichmeyer , Gregory Paul Nitzel , Merrill Lynn Schaeffer
摘要: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
-
公开(公告)号:US09987349B2
公开(公告)日:2018-06-05
申请号:US15076381
申请日:2016-03-21
发明人: Michael B Roof , Phillip Wayne Hayes , Marc Allan Eichmeyer , Gregory Paul Nitzel , Merrill Lynn Schaeffer
CPC分类号: A61K39/12 , A61K2039/5252 , A61K2039/5256 , A61K2039/5258 , A61K2039/545 , A61K2039/552 , A61K2039/55516 , A61K2039/55555 , A61K2039/55566 , C12N7/00 , C12N2750/10022 , C12N2750/10023 , C12N2750/10034 , C12N2750/10051 , C12N2750/10071 , C12N2750/14143
摘要: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
-
公开(公告)号:US20180169214A1
公开(公告)日:2018-06-21
申请号:US15886531
申请日:2018-02-01
IPC分类号: A61K39/12 , G01N33/569 , C07K14/005 , C12N7/00 , A61K39/00
CPC分类号: A61K39/12 , A61K2039/545 , A61K2039/55 , A61K2039/552 , A61K2039/55511 , A61K2039/55566 , C07K14/005 , C12N7/00 , C12N2710/14143 , C12N2710/14163 , C12N2750/10022 , C12N2750/10034 , C12N2750/10051 , C12N2770/10034 , G01N33/56983
摘要: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
-
公开(公告)号:US20170253908A1
公开(公告)日:2017-09-07
申请号:US15456013
申请日:2017-03-10
发明人: Marc Allan Eichmeyer , Michael B. Roof , Merrill Lynn Schaeffer , Eric Martin Vaughn , Kun Yang , Jeremy Richard Rush , Daniel John Murfin
IPC分类号: C12Q1/37 , G01N33/569 , C07K7/06 , C07K14/00 , C07K7/08 , G01N33/68 , C07K14/005
摘要: The invention provides methods and mass-labeled peptides for use in said methods for quantifying the presence of a one or more viral proteins in a sample of a preparation containing agents which bind to said viral protein, using mass-spectroscopic analyses of the sample and standards containing known amounts of labeled and unlabeled signature peptides, in particular wherein said viral proteins are antigens in a vaccine for porcine circovirus.
-
-
-
-
-
-
-
-
-